During the last session, Atara Biotherapeutics Inc (NASDAQ:ATRA)’s traded shares were 0.53 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $0.69, reflecting an intraday loss of -1.40% or -$0.01. The 52-week high for the ATRA share is $3.02, that puts it down -337.68 from that peak though still a striking 71.01% gain since the share price plummeted to a 52-week low of $0.20. The company’s market capitalization is $82.36M, and the average trade volume was 2.68 million shares over the past three months.
Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information
Atara Biotherapeutics Inc (ATRA) registered a -1.40% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.40% in intraday trading to $0.69, hitting a weekly high. The stock’s 5-day price performance is 4.39%, and it has moved by -1.43% in 30 days. Based on these gigs, the overall price performance for the year is -74.73%.
Atara Biotherapeutics Inc (ATRA) estimates and forecasts
Statistics show that Atara Biotherapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Atara Biotherapeutics Inc (ATRA) shares have gone down -47.73% during the last six months, with a year-to-date growth rate more than the industry average at 50.19% against 12.90. In the rating firms’ projections, revenue will increase 1,043.60% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 24.69M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 31.3M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.23M and 3.77M respectively. In this case, analysts expect current quarter sales to grow by 1,913.90% and then jump by 730.20% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 13.12%. While earnings are projected to return 79.08% in 2024.
ATRA Dividends
Atara Biotherapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
